According to GLOBOCAN 2018, prostate cancer is the third most prevalent cancer in both men and women, as well as the second most common cancer in males worldwide.[6,7] Obesity at a young age delays puberty and may lead to a lower lifetime exposure to insulin-like growth factor 1, which may influence prostate cancer development later in life.[8,9] Elevated lipid levels and lipid signaling, inflammatory responses, insulin resistance, and adipokines have all been proposed as pathways to explain the association between cancer and obesity. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.